ViaCyte to Present at Upcoming Healthcare Events
SAN DIEGO, February 17, 2016 — ViaCyte, Inc., a privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy for the treatment of diabetes in clinical-stage development, today announced three presentations at upcoming healthcare events.
Details of the presentations are as follows:
Event: Regenerative Medicine: Transitioning Therapeutics from Cells to the Clinic
Title: Development of Stem-Cell Derived, Macroencapsulated Islet Replacement for Type 1 Diabetes
Speaker: Dr. Thomas Schulz, Director, ES Cell Technology
Date/Time: February 22, 2:35 p.m. EST
Location: New York Academy of Sciences Conference Center, New York, NY
Event: The 2nd Saudi International Biotechnologies Conference 2016
Title: Chasing a Cure for Type 1 Diabetes: The Development of a Stem Cell Derived Islet Replacement Therapy
Speaker: Dr. Paul Laikind, President and CEO
Date/Time: February 23, 9:15 a.m. AST
Location: KACST Headquarters, Conference Hall, Riyadh, Saudi Arabia
Event: American Society of Transplantation: Pipeline Presenters
Speaker: Dr. Kevin D’Amour, Vice President, Research and CSO
Date/Time: February 25, 11:00 a.m. MST
Location: Arizona Biltmore, Phoenix, Arizona
ViaCyte’s VC-01™ product candidate, a first-in-class cell replacement therapy for the treatment of type 1 diabetes, is currently being evaluated in a Phase 1/2 trial called STEP ONE, or Safety, Tolerability, and Efficacy of VC-01 Combination Product in Type One Diabetes. More info on the clinical trial is here: https://clinicaltrials.gov/ct2/show/NCT02239354.
For more information about ViaCyte’s participation in industry events, please visit: http://viacyte.com/news-events-2/viactye-events/
ViaCyte is a privately-held regenerative medicine company focused on developing a novel cell replacement therapy for the treatment of diabetes. ViaCyte is conducting a Phase 1/2 clinical trial of the Company’s lead VC-01 product candidate in patients with type 1 diabetes who have minimal to no insulin-producing beta cell function. ViaCyte’s VC-01 combination product candidate is based on the production of pancreatic progenitor cells derived from human pluripotent stem cells. These progenitor cells are implanted in a durable and retrievable encapsulation device. Once implanted and matured, these cells are designed to secrete insulin and other regulatory factors in response to blood glucose levels. The VC-01 product candidate is being developed as a potential long-term diabetes treatment with the goal of reducing the risk of hypoglycemia and diabetes-related complications without requiring long-term immune suppression.